Lucero Bio

Ready-to-Use Liver Spheroid Plates for Drug Discovery

Cryopreserved Assay-ready Liver Spheroids

Go from freezer to assay in 24 hours — no culturing, no delays
384-well format — uniform, high-throughput, reproducible
2-step AI-driven QC for batch-to-batch uniformity
Compatible with all downstream instrumentation
Built for pharma standards

Learn more

Black_plates_transparent-removebg-preview

Made for for early-stage ADME, tox, and PK/PD workflows.

Scale

Preloaded with 384 fully formed 3D tissue

Speed

Start testing in <24 hours

Reliability

AI-driven QC for maximum batch-to-batch uniformity

Usability

Compatible with existing workflows – no new equipment needed

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

The Lucero Difference
Freezer to Assay in 24 hours

Day 1

Day 2

QUALIFIED SPHEROIDS

THAW AND USE

Go from freezer to assay in 24 hours

Day 1

Pre-seeded plates with qualified spheroids Low contamination risk

Day 1

Day 2

Thaw and use Ready for compound dispensing, washing, fixing, staining, and imaging

Day 2

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

Day 1

Day 7

QUALIFIED SPHEROIDS

THAW AND USE

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

Day 1

Day 7

QUALIFIED SPHEROIDS

THAW AND USE

What Lucero's assay-ready 3D models can do

Our accurate tool for screening and selecting winning drugs.

QUICKER DECISION MAKING

100% well population with viable and uniform spheroids

SAVES 7 DAYS WORKTIME

Scientists can avoid the hassle of culturing (or contaminating) spheroids

EASE OF USE

Thaw and use plates when required. Never miss a project deadline. Product works the same every time

The Lucero Advantage

Lucero is built to lead Our assay-ready plates beat the competition in scale, quality, speed, and usability.

Scale: Our 10 Scale Lucero's plates come preloaded with 384 fully formed scaffold-free 3D culture.
Speed: Researchers don't wait days for cultures to form. They thaw a plate, and they're testing within 24 hours.
Reliability: Our platform uses microfluidics and AI to qualify, sort, and dispense spheroids. This leads to better consistency compared to the industry standard of culturing spheroids in wells which can result in 20-30% of wells not producing data.
Usability: Lucero's plates fit seamlessly into the workflows researchers already use today.

Sign Up for Our Newsletter

The #1 Newsletter for 3D cell culture science & innovation

Never miss an exciting event or publication in the 3D culture space again
Learn from cutting-edge scientists in the field from around the world
Discovery collaboration & funding opportunities to advance your research
Feature your breakthrough research

About Us

Lucero was founded in response to the growing need for better 3D cell culture tools in early-stage pharmaceutical drug discovery.

We enable quicker and more accurate decision making in drug development with our cryopreserved assay-ready spheroid plates.

Our assay-ready plates are loaded with pre-qualified spheroids and optimized for high-throughput workflows in pharma.

No culturing. No variability. Just thaw and test.

2020

Lucero was founded in Gothenburg, Sweden, in response to the desperate need for better in-vitro models for drug testing.

Awarded €150,000 ERC Proof of Concept grant to kickstart early R&D and product validation.

2020

2021

Joined Vinnova-backed pharma consortium & moved into AstraZeneca’s BioVentureHub.

Began co-developing automated 3D cell culture tools with large pharma, academic, and SME partners.

2021

2022

Advanced R&D on scalable liver spheroid platform using AI and microfluidics based on user feedback.

2022

2023

Secured €1.3M EIC-Transition grant to accelerate commercialization.

2023

2024

Filed patent for novel method of 3D model QC and plate preparation, protecting Lucero’s USP and competitive advantage.

2024

2025

Developing novel cryopreservation protocols for liver spheroid models & raising Seed round to launch product in 2026.

2025

Awards

Cryopreserved Assay-ready Liver Spheroids

Made for for early-stage ADME, tox, and PK/PD workflows.

Scale

Preloaded with 384 fully formed 3D tissue

Speed

Start testing in <24 hours

Reliability

AI-driven QC for maximum batch-to-batch uniformity

Usability

Compatible with existing workflows – no new equipment needed

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

The Lucero DifferenceFreezer to Assay in 24 hours

Day 1

Day 2

QUALIFIED SPHEROIDS

THAW AND USE

Go from freezer to assay in 24 hours

Pre-seeded plates with qualified spheroids Low contamination risk

Thaw and use Ready for compound dispensing, washing, fixing, staining, and imaging

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

Day 1

Day 7

QUALIFIED SPHEROIDS

THAW AND USE

How It's Done Today

Day 1

Day 7

Day 8

CULTURE SPHEROIDS

COLLECT AND SUSPEND

SORT AND DISPENSE

"READY" FOR ASSAY

Day 1

Day 7

QUALIFIED SPHEROIDS

THAW AND USE

What Lucero's assay-ready 3D models can do

Our accurate tool for screening and selecting winning drugs.

QUICKER DECISION MAKING

100% well population with viable and uniform spheroids

SAVES 7 DAYS WORKTIME

Scientists can avoid the hassle of culturing (or contaminating) spheroids

EASE OF USE

Thaw and use plates when required. Never miss a project deadline. Product works the same every time

The Lucero Advantage

Sign Up for Our Newsletter

Sign Up for Our Newsletter

The #1 Newsletter for 3D cell culture science & innovation

About Us

Lucero was founded in Gothenburg, Sweden, in response to the desperate need for better in-vitro models for drug testing.

Awarded €150,000 ERC Proof of Concept grant to kickstart early R&D and product validation.

Joined Vinnova-backed pharma consortium & moved into AstraZeneca’s BioVentureHub.

Began co-developing automated 3D cell culture tools with large pharma, academic, and SME partners.

Advanced R&D on scalable liver spheroid platform using AI and microfluidics based on user feedback.

Secured €1.3M EIC-Transition grant to accelerate commercialization.

Filed patent for novel method of 3D model QC and plate preparation, protecting Lucero’s USP and competitive advantage.

Developing novel cryopreservation protocols for liver spheroid models & raising Seed round to launch product in 2026.

Venture Cup: Idea Hunt

Top 20 business ideas, Sweden

2019

SPIE Startup Challenge

Semi finalists

2020

Venture Cup: Startup

Regional finalists

2020

The Lucero Difference
Freezer to Assay in 24 hours